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Inherited bleeding disorders (IBDs) comprise an extremely heterogeneous group of
diseases that reflect abnormalities of blood vessels, coagulation proteins, and pla-
telets. Previously the UK‐GAPP study has used whole‐exome sequencing in com-
bination with deep platelet phenotyping to identify pathogenic genetic variants in
both known and novel genes in approximately 40% of the patients. To interrogate
the remaining “unknown” cohort and improve this detection rate, we employed an
IBD‐specific gene panel of 119 genes using the Congenica Clinical Interpretation
Platform to detect both single‐nucleotide variants and copy number variants in 126
patients. In total, 135 different heterozygous variants in genes implicated in
bleeding disorders were identified. Of which, 22 were classified pathogenic, 26
likely pathogenic, and the remaining were of uncertain significance. There were
marked differences in the number of reported variants in individuals between the
four patient groups: platelet count (35), platelet function (43), combined platelet
count and function (59), and normal count (17). Additionally, we report three novel
copy number variations (CNVs) not previously detected. We show that a combined
single‐nucleotide variation (SNV)/CNV analysis using the Congenica platform not
only improves detection rates for IBDs, suggesting that such an approach can be
applied to other genetic disorders where there is a high degree of heterogeneity.
K E YWORD S
CNV, inherited bleeding, platelet disorders, SNV, thrombocytopenia, variant interpretation,
whole‐exome sequencing
1 | INTRODUCTION
Inherited bleeding disorders (IBDs) are a heterogeneous group of
diseases that reflect abnormalities in blood vessels, coagulation
proteins, and platelets. They often present after birth or during
childhood, and clinically manifest with variable bleeding tendencies
(Blanchette et al., 1991). Although the majority of IBDs are known to
be primarily associated with coagulation factor abnormalities such as
hemophilia A and B, rarer disorders of platelet count and function
are still poorly understood (Sivapalaratnam et al., 2017). Therefore,
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to investigate the molecular mechanisms of this group of disorders, it
is often best to address the gene(s) already implicated in these
bleeding disorders in the first instance, and then specifically to in-
vestigate how the genetic variants can disrupt the gene function
(Nurden et al., 2012; Peyvandi et al., 2006). An increasing number of
new genes and their variants have been discovered, which are im-
plicated in megakaryocyte differentiation and/or platelet production
and function (Johnson, Fletcher, et al., 2016).
The UK Genotyping and Phenotyping of Platelets study
(UK‐GAPP; https://www.birmingham.ac.uk/research/cardiovascular-
sciences/research/platelet-group/platelet-gapp/index.aspx) has re-
cruited over 1000 patients based on a history of suspected bleeding
disorders of unknown cause from over 25 collaborating hemophilia
care centers across the United Kingdom. Recruited patients under-
went a combination of platelet phenotyping and genotyping to de-
termine the likely causative genes attributable to their specific
defects (Jones et al., 2012; Watson et al., 2013). Gross hematological
analysis and light transmission aggregometry and/or flow cytometry
were used to identify thrombocytopenia (low platelet counts), pla-
telet function, and cell signaling defects. Following this, targeted
genetic analysis was employed and revealed variants, both novel and
known, to be causative of bleeding in patients.
High‐throughput sequencing technologies including whole‐
exome sequencing (WES) and whole‐genome sequencing are valu-
able tools used to uncover novel variants in platelet‐specific genes.
Over the past 10 years, such techniques have revealed many cau-
sative variants, therefore assisting in providing a clear diagnosis for
some patients with severe bleeding disorders (Bastida et al., 2018;
Daly et al., 2014; Downes et al., 2019; Leinøe et al., 2017). In addi-
tion, targeted next‐generation sequencing (NGS) panels can be used
to highlight platelet‐specific genes that have been previously im-
plicated in bleeding disorders. NGS panels can be employed in a
clinical diagnostic setting or used for prescreening, filtering out pa-
tients with variants in known genes, and subsequently employing
WES for those who may harbor variants in novel genes (Johnson
et al., 2018; Simeoni et al., 2016). This approach was applied in the
UK‐GAPP study where patients with known mutations in hemophilia
A and B or coagulation mediated genes, known to cause bleeding
were eliminated. However, many of these panels do not search for
copy number variations (CNVs), and indeed we, and others have not
found definitively causative variants in approximately 40%–50%
patients despite a strongly indicative inherited component for their
bleeding (Bastida et al., 2018; Johnson et al., 2018; Johnson, Lowe,
et al., 2016; Leinøe et al., 2017; Lentaigne et al., 2016). In this study,
we address this by applying a newly established, comprehensive
genetic analysis software that detects both single‐nucleotide varia-
tions (SNVs) and CNVs. Congenica (https://www.congenica.com) is
an automated clinical decision support platform that was used to
analyze and rapidly interpret the WES data of 126 patients recruited
to the UK‐GAPP study. Users are able to prioritize and review ge-
netic variants, as well as assign pathogenicity, after which the soft-
ware calculates overall pathogenicity based on the American College
of Medical Genetics and Genomics (ACMG) guidelines (Richards
et al., 2015). It collates all essential information to make an informed
and robust decision for the identification of causal genetic variants.
The Congenica platform is primarily applied for genetic diagnostics
and is routinely used in clinical laboratories for variant validation and
reporting. For the first time, we show its utility in interrogating a large
cohort of patients recruited to the UK‐GAPP research study. Using this
approach, we perform a robust and comprehensive analysis to find both
known and novel genetic variants with plausible association with dis-
ease, including rare CNVs not previously detected. Combined with
extensive patient phenotypic studies, this provides a potent tool for the
dissection of the genetic causes of bleeding in a cohort which, thus far,
remains genetically unresolved despite an extensive clinical presenta-
tion of familial bleeding.
2 | METHODS
2.1 | Hematological evaluation and platelet
phenotyping of patients
To initially classify patients as having a platelet defect and determine
their platelet defect subtypes, they underwent an initial hematolo-
gical workup and extensive platelet function testing workflow. These
methods can be seen in detail in the Supporting Information Meth-
ods section.
2.2 | WES
WES was performed on the genomic DNA of 117 patients in this
study as previously described (Johnson, Lowe, et al., 2016). Briefly
following enrichment of coding regions and intron/exon boundaries
with the SureSelect human AllExon 50Mb Kit (Agilent Technologies),
captured libraries were sequenced on the Illumina HiSeq 2500
(Illumina) with 100‐bp paired‐end reads.
2.3 | Processing WES data using Congenica
software
First, an Interpretation Request (IR) was completed which included
information about the proband and any other family members and
related clinical data including HPO terms (abnormal bleeding
HP:0001892 and/or thrombocytopenia HP:0001873) for affected
individuals. Relevant gene panels (Inherited Bleeding Disorder; High
Evidence_Green, Medium Evidence Amber and Low Evidence Red,
gene lists) containing 119 genes (Table S1) from Panel app (https://
panelapp.genomicsengland.co.uk/) were applied in the project and
deemed suitable for research purposes. However, of this gene panel
only 88 genes from the Genomics England website (R90) are con-
sidered as suitable for clinical use at this present time. The WES data
(either BAM or FASTQ files) of patients were then transferred to the
Congenica SFTP server for processing. The Congenica pipeline could
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then be used for sequence alignment and variant calling of SNVs,
small insertion/deletion (indels), CNVs (Figure 1), and coverage
(Table S3).
The analytical pipeline for the detection of CNVs in genes in-
volved in the IBDs panel was employed using the ExomeDepth
coverage approach. The exome read depth of the target patient's
sample was compared against the read depth of a reference panel
(up to 10 WES samples of each gender) to detect regions with dif-
ferent coverage which could represent a CNV event.
Using the Congenica software, the lower limit that the Exome-
Depth calling software uses for CNV calling is ≥20 sequence reads.
This ensures that ExomeDepth does not consider low quality reads
when comparing the reference samples to the target patient.
3 | RESULTS
3.1 | Platelet phenotyping
Recruited patients were subjected to an initial hematological analysis
and extended deep platelet phenotyping using the previously pub-
lished workflow (Johnson, Lowe, et al., 2016). Phenotyping outcomes
can be seen in detail in the Supporting Information Results section
(Figures S1 and S2; Table S2).
3.2 | Validation of WES analysis with known
variants
Validation of the WES analysis in the GAPP study was performed
using Congenica software. Five different known genetic variants
were identified previously by WES in nine patients with a suspected
IBD (Fletcher et al., 2015; Johnson, Lowe, et al., 2016; Table 1). We
used two trios (one parent and two affected children) and three
unrelated individuals, all with known or likely pathogenic variants in
platelet‐ or megakaryocyte‐related genes. This analysis was con-
ducted in a blind manner to assess the reliability and robustness of
the software in correctly highlighting all known genetic variants in
these patients. Using panels of genes implicated in IBDs, the first trio
(Family A) including exomes of patients 1–3 were found to share the
same splicing sequence variant in RUNX1; c.98‐1G>A. The second
trio (Family B) including exomes of patients 4–6 all shared a variant
c.503G>T p.(Cys168Phe) in GFI1B. Patient 7 displayed a homozygous
missense mutation c.1246G>A p.(Gly416Arg) in the GNE gene. In
F IGURE 1 Congenica pipeline overview for
processing of whole‐exome sequencing (WES)
data. Adapted from https://www.congenica.com/.
The informatic strategy shown is used to
incorporate both single‐nucleotide variation
(SNV) and copy number variation (CNV) analysis.
The raw WES data are inputted as either FASTQ,
or BAM files followed by alignment to the
reference genome. SNV calling is then performed
to generate VCF files and subsequent in silico
tools to determine the pathogenicity of variants.
Simultaneously, CNV analysis is performed using
a predefined reference and sex‐matched WES
panel and fed into ExomeDepth for CNV calling in
the WES samples
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patient 8, a missense variant c.659T>A p.(Val220Asp) in SLFN14 and
finally in patient 9, a stop gain mutation c.1611C>A p.(Cys537Ter)
located within THBD was identified. All known variants found in the
patients were successfully verified by Congenica software against
our previously analyzed WES data (Table 1).
3.3 | WES analysis to identify new SNVs and CNVs
using the Congenica platform
WES data of all 117 patients were analyzed by the Congenica platform
based on the ExomeDepth coverage following the phenotyping and
platelet function studies workflow. The Congenica pipeline was used for
exome sequence alignment and variant calling of SNVs, indels, and
CNVs to determine plausible candidate variants from the WES data. An
average read depth sequencing coverage of 205 was observed at the
site of each variation across all DNA samples analyzed by WES for
SNVs (Table S3). The ExomeDepth integrated tool was used to de-
termine CNV based on read coverage (Table 3). First, WES data of the
117 patients were analyzed by filtering using an IBDs gene panel
(Table S1). Variants were then filtered within the software based on the
exclusion criteria initially stated in the GAPP study. A rare variant cut‐
off or minor allele frequency (MAF) of <0.01 in each data set was used
and synonymous and intron variants ±5 base pairs away from the
exon–intron boundaries were excluded. Non‐shared variants between
the same affected family members were also eliminated.
Following exclusion of variants based on these criteria, a range
of between two and six variants (SNVs, small indels, and splice site)
were noted per patient (Table 2). In silico pathogenicity prediction
tools that have been integrated into the Congenica software were
employed for further analysis (Table 2). A total of 135 variants in
genes implicated in bleeding disorders were identified across all the
117 patients and all variants were observed in a heterozygous state
(Table 2). In total, 22 variants were classified as pathogenic and 26
were likely pathogenic when considering the ACMG consensus
guidelines. The remaining 87 variants were classified as of uncertain
significance. The graphical illustration of this summary is shown in
(Figure 2a). There was a marked difference in the number of re-
ported variants between the four classes of variants in patient
groups: platelet count (35); platelet function (43); combined platelet
count and function (59); and normal count (17) (Figure 2b).
3.4 | Candidate variants identified in patient's
cohort
A total of 48/135 (35.5%) variants with MAF of 0, unless otherwise
stated, were identified across the 117 patients (Table 2). In total,
14/48 (29.1%) variants have been published previously. The number
of variants found to be shared in the same affected family members
were 21. Plausible candidate variants were present within the fol-
lowing genes (RUNX1, SLFN14, FLI1, ETV6, HPS3, F10, P2RY12,
SMAD4, TUBB1, GP1BA, GBA, CYCS, VWF, THBD, LYST, ADAMTS13,
GFI1B, ITGA2B, NBEAL2, MECOM, and MYH9; Table 2). Two rare
variants were noted between five related affected family members
including RUNX1: c.611G>A p.(Arg204Gln) in patients 38.1 and 38.2;
WAS: c.1456G>A p.(Glu486Lys) in patients 38.3, 38.4, and 38.5; and
a stop gain variant within ADAMTS13: c.1315G>T p.(Glu439Ter) was
shared between two related affected individuals 53.1 and 53.2. Two
related affected individuals with macrothrombocytopenia shared a
variant within the newly discovered gene (involved in platelet dis-
orders) MECOM: c.951G>T p.(Lys317Asn). A novel stop gained var-
iant within ETV6: c.1288C>T p.(Arg430Ter) was noted in patient 7,
which was subsequently classified as pathogenic.
3.5 | CNVs found in the patient cohort
Overall, the CNV analysis using the integrated ExomeDepth tool
revealed an average of four CNVs per exome (n = 15; Table 3). There
were three rare structural variants covering large regions on chro-
mosomes 11 and 17 and encompassing numerous genes, including
TABLE 1 Nine patients and the five
known candidate variants used for
validation of the Congenica software
Patient Gene Variation Type
(Family A) 1 RUNX1 (Zhang et al., 2018) c.98‐1G>A Splice acceptor
(Family A) 2 RUNX1 c.98‐1G>A Splice acceptor
(Family A) 3 RUNX1 c.98‐1G>A Splice acceptor
(Family B) 4 GFI1B (Rabbolini et al., 2017) c.503G>T p.(Cys168Phe) Missense
(Family B) 5 GFI1B c.503G>T p.(Cys168Phe) Missense
(Family B) 6 GFI1B c.503G>T p.(Cys168Phe) Missense
7 GNE c.1246G>A p.(Gly416Arg) Missense
8 SLFN14 (Johnson, Lowe, et al., 2016) c.659T>A p.(Val220Asp) Missense
9 THBD (Rabbolini et al., 2017) c.1611C>A p.(Cys537Ter) Stop gain
Note: NCBI reference sequences: RUNX1 (NM_001001890.3); GFI1B (NM_001371908.1); GNE
(NM_000157.4); SLFN14 (NM_001129820.1); THBD (NM_000361.2).
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candidate genes within the IBD gene panel. First, a rare 604‐kbp
CNV loss was noted on chromosome 11q24.3 in patient 35 which
covered nine genes including FLI1. A further rare deletion was found
on chromosome 11q24.3 in patient 71 which covered 31 genes in-
cluding FLI1 (Figure 3a,b).
Following ExomeDepth alignment with a panel of controls the reads
ratio was around 0.5 which indicates heterozygosity, as observed in
Table 3. A rare CNV gain was noted in patient 45 within TBXA2R on
chromosome 19p13.3 and containing four genes in total (Figure 3c). The
CNV reads ratio was 2.72 which is indicative of a heterozygous insertion.
3.6 | Oligogenic findings in patient cohort
Within the patient cohort there were several examples of potential
oligogenic inheritance involving either two or more gene variations
from the IBD gene panel. Of particular interest was patient 16 who
demonstrated an apparent pathogenic missense variant in RUNX1 and
a likely pathogenic variant in ITGB3, both of which are plausible can-
didate variants to explain the thrombocytopenia and bleeding history
observed. Patient 20 harbored two heterozygous missense variants
within GP6 and THBD in which the patient had a platelet function
disorder and episodes of bleeding. In patient 30, likely pathogenic and
pathogenic variations were found in GP1BA and GBA respectively.
Again this patient had a low platelet count and a history of bleeding.
4 | DISCUSSION
NGS approaches have increasingly been used over the last decade in
the molecular diagnosis of IBD. Here, we present a large‐scale ap-
plication of WES analysis by using a robust molecular diagnostics
platform for diagnosis of 117 patients recruited to the UK‐GAPP
study. The aim was to assess the ability of Congenica software to
analyze WES data of the patients for both sequence and structural
variants by targeting a known panel of IBD genes. Subsequently,
patients with variants in known bleeding disorder genes can be
eliminated by a series of filtration steps and WES data targeted for
those with undetected variants who may harbor a variant in novel
genes. We included and applied a total of 119 genes to our patient
cohort for filtering; it is, however, important to note that currently
only 88 of these genes are considered clinical‐grade genes according
to Genomics England. The remainder of the genes may become
clinical grade once more variants are identified in patients and
deemed pathogenic over time.
Phenotypic presentation and platelet counts varied considerably
among our recruited patients, which is consistent with the variability
of clinical presentation between patients with suspected IBDs.
However, the majority of patients 33/117 (28.2%) were noted with a
platelet function defect and 23/117 (19.6%) patients represented
thrombocytopenia. Of the 117 recruited patients, 15 (12.8%) were
deemed to have a macrothrombocytopenia. Platelet function studies
revealed the presence of a combination of platelet defects in addi-
tion to thrombocytopenia in 36/117 (30%) of patients. The majority
of the patients with platelet defects displayed both secretion and Gi
defects (Supplementary figure S2). However, a previous study has
shown that some patients with normal lumi‐aggregeometry results
have platelet spreading defects, indicating the difficulties faced when
diagnosing patients with IBDs and the multitude of assays required
for platelet phenotype disorders to be diagnosed (Khan et al., 2020).
Overall, a total of 135 variants in genes implicated in bleeding
disorders were identified across all 117 patients and all variants
were observed in a heterozygous state, implicating dominant in-
heritance patterns. The study has shown that the majority of
F IGURE 2 Pathogenicity prediction of
genetic variants based on the American
College of Medical Genetics and Genomics
consensus guidelines. (a) Classification of
variants based on the pathogenicity
prediction analysis. (b) Number of
reported variants for the patients in each
different class of platelet phenotype
observed
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plausible candidate variants were associated with IT genes which
explain the association of thrombocytopenia with platelet defects in
the majority of patients. When considering pathogenicity prediction,
22 patients were classified as pathogenic and 26 patients as likely
pathogenic, while 87 patients had uncertain pathogenicity and
therefore classified as uncertain significance. A targeted WES ana-
lysis was previously carried out on some patients which identified
genetic variants in inherited thrombocytopenia with or without
secondary qualitative defects (Johnson et al., 2018; Johnson, Lowe,
et al., 2016). This study has conclusively identified these genetic
variants, which indicates the ability of the Congenica platform to
analyze and provide suitable validation of WES data in these
patients.
If we compare the performance of the Congenica tool em-
ployed here with other bioinformatic platforms we observe the
following: 25 variants were identified by the Congenica software as
well as other bioinformatic tools and the majority of them were
either pathogenic or likely pathogenic. A further 24 variants were
classified as pathogenic or likely pathogenic by the Congenica
software only. Therefore, this showed that the Congenica software
is a more robust tool to analyze WES as it provides a higher variant
detection rate compared with other bioinformatic tools. It is also
important to note that we did not include variants of uncertain
significance here in this evaluation as it is difficult to assign caus-
ality but are still plausible pathogenic varaints. Congenica software
also has the added benefit of detecting CNVs, a process which is
notoriously difficult yet valuable in identifying rare causative var-
iants in heterogeneous diseases. Congenica utilizes the integrated
ExomeDepth tool to compare a target with reference and here,
identified rare CNVs in this population. Congenica software
alongside targeted gene panel searching, allows for efficient and
accessible detection of variants and with some clinical interpreta-
tion will be a valuable tool when analyzing large datasets
(Nowakowska, 2017; Valsesia et al., 2012).
Paris‐Trousseau syndrome, characterized by a bleeding defect
with large α‐granules and abnormal megakaryocyte morphology is
well documented, which is caused by a dominant inheritance of q23
deletion on chromosome 11 (Stevenson et al., 2015). Patients with
this disorder have variable size of chromosomal deletion associated
with different components of the syndrome. A hemizygous deletion
of FLI1 was attributed to the platelet defect in two individuals of our
cohort. These CNVs noted in patients 35 and 71 cover the deletion
region in FLI1 and are also surrounded by several flanking genes.
Both patients presented with thrombocytopenia and a secretion
defect which suggest the platelet phenotype and the CNVs in FLI1 to
be associated with their disorders. Thromboxane receptor deficiency
is an autosomal recessive or dominant disorder characterized by
bleeding symptoms associated with quantitative or qualitative de-
fects within the thromboxane receptor (Mundell & Mumford, 2018).
Although we did not find any plausible candidate SNVs in the 119
candidate genes or the thromboxane receptor in patient 45, we did
note a rare CNV duplication in the TBXA2R gene and deduce that
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which were also detected, could be causative of the patient's
thrombocytopenia and bleeding. In the future, it would be interesting
to investigate these CNVs further to determine the extent of the
contiguous deletions or insertions by long‐range polymerase chain
reaction and sequencing to determine the breakpoints and me-
chanisms of the variant, as well as confirming these regions using
multiplex ligation‐dependent probe amplification, should kits be
available for these genomic regions.
F IGURE 3 Copy number variants found in cohort of GAPP patients. Screenshots from the Congenica software CNV/structural
variant tab in patients showing (a) copy number variant (loss) found in patient 35 which includes FLI1 and eight other genes on
chromosome 11q24.3; (b) copy number variant (loss) found in patient 71 which includes FLI1 and 30 other genes on chromosome
11q24.3; and (c) copy number variant (gain) found including TBXA2R in patient 45 and three other genes within chromosome 19p13.3
F IGURE 3 Continued
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In summary, we show validation and a practical approach of a
robust diagnostic platform that can be employed for WES analysis. In
this study, we use data from a cohort of patients with suspected
IBDs; a broad category of diseases, well acknowledged in the he-
matology field as difficult to classify and associate to single causative
genetic abnormalities. This study has shown the ability of the soft-
ware to detect CNVs with high efficiency with the use of targeted
gene panels as a replacement of traditional methods for detect-
ing CNVs.
To conclude, our data reveals use of a highly sensitive and va-
luable tool which can be used for detecting SNVs and CNVs based on
WES data. To our knowledge, this is one of the first studies, although
in a research setting, to implement this software for both SNV and
CNV analysis. We see this as a leap forward in the ability to classify
highly complex disorders with a high degree of heterogeneity within
the wider scientific community providing concise and definitive di-
agnosis for patients.
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